Company Analysis: UnitedHealth Group (NYSE: UNH)

From legal challenges and violations plummeting the stock, to Warren Buffett's company, Berkshire Hathaway, buying 5 million shares, UnitedHealth Group poses an interesting investment case. Currently, the company is facing major litigations and federal investigations and is down 29% year to date. The question arises: Is UNH at a discount, or will this company implode?

Company Overview

UnitedHealth Group Inc (NYSE: UNH) is a healthcare and well-being compnay based in the United States, and headquartered in Minneapolis, Minnesota. UNH serves clients across the state and in over 100 countries worldwide. UNH business segments can be split into two groups: UnitedHealthcare: This segment provides a range of health benefits and insurance products for both employers and individuals. This includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Optum: A service platform that delivers data, pharmacy care, and health management solutions. Some products include Optum Health, which helps patients and providers navigate and address complex, chronic and behavioural health needs. Optum Rx offers a range of pharmacy care services through retail pharmacies or by delivery.

UNH Healthcare holds 20% of the market. Together with its peers (CVS, Cigna, Elevance, Humana, Centene, Molina), it controls 55% of the market, highlighting the intense competition of this industry.

Key Metrics (in $)

Market Cap	Revenue	EBITDA	Operating Margin	Operating Cash Flow	Trailing P/E	Diluted EPS (ttm)	Medical Loss Ratio
333B	400.3B	34.9B	4.61%	28.96B	15.31x	23.09	85.5%

Share Price: July 2024 - Present

Recent News

UNH stock plummeted as low as $237 over the past 52 weeks. As of 10/10/25, it is up 52% from a Low of $356. There are a lot of contributing factors that caused the price to drop and rise over the past few months that we'll summarise below.

February 2024 - Antitrust Investigation: The Department of Justice announced an investigation into UNH over Optum's acquisition of physician practices.

November 2024 - Peak Stock Price: UNH reached its all-time high at $630 in November 2024

December 2024 - CEO Assassination: Brian Thomson, the CEO at that time, was killed in New York in a targeted attack. The killing highlighted public outrage against health insurance companies accused of putting profits over patients.

April 2025 - First Earnings Miss Since 2008: The firm reported adjusted EPS of $7.20, its fist miss in decades. This can be blamed on higher-than-expected medical costs, which crunched operating margins from 8.8% to 7.3%. At this time, the stock declined to around $300.

May 2025 - CEO Resignation & Guidance Suspension: The new CEO, Andrew Witty, suddenly stepped down as CEO due to "personal reasons" and was replaced by Stephen Hemssely. At the same time, the company suspended its 2025 outlook due to accelerating care activity and higher-than-expected Medicare Advantage costs. The stock price fell a further 10%.

June 2025 - Whistleblower Allegations: US representatives urged the DOJ to expand its investigations as ex-employees accused UNH of using improper tactics to gain Medicare Advantage enrollees and paying nursing homes to reduce hospital transfers.

July 2025 - DOJ Medicare Billing Investigation: Adding flame to the fire, the DOJ Investigators looked into billions of medical claim records and found that insurers may be responsible for $50 billion in fraud related to Medicare Advantage between 2019 and 2021, receiving payments for "hundreds of thousands of questionable diagnoses that triggered extra taxpayer-funded payments". UNH acknowledged this for the first time in July 2025, stating they're cooperating with criminal and civil DOJ investigations into Medicare Advantage billing practices. Some investors are concerned about UNH's profitability since UNH can't "systematically overcharging the government" anymore.

August 2025 - Stock Hits Bottom & Berkshire Investment: August 1st, investors are rattled by the ongoing DOJ investigations, and the stock hit its lowest of $237.

However, in the same month, it was revealed that Warren Buffett's Berkshire Hathaway purchased more than 5 million shares in Q2 2025, securing a stake worth approximately $1.6 billion. The share price rose 6% as investor confidence renewed.

September Onwards - Markets are booming, and markets are divided on the positioning of UNH. Analysts are rating strong buys, and the stock is up at $356. Is this short-term optimism, or can UNH grow despite legal and profitability concerns?

Market Consensus

Analyst Ratings:  Out of 28 analysts, 6 recommend "Strong Buy", 13 recommend "Buy", 6 recommend "Hold", and only 3 recommend "Sell".

Price Targets: Average price target is $362, with some analysts targeting as low as $190 and as high as $410.

Institutional Activity: As mentioned earlier, Berkshire Hathaway's involvement signals a Buy.

It's clear that markets see this as an opportunity, but investing in UNH doesn't come without risks.

Investment Thesis

DCF Valuation

Using a WACC of 6.7% and a five-year time horizon, the base case assumes revenue growth of 7% and a slow decline, with MLR (insurance claims) growing slowly at around 6% and also declining over time. Our base case scenario implies a target price of $455.06, our bear case implies a target of $280.28, and our bull case implies a target of $638.98.

The DCF accounts for operational efficiency and demographic growth (an ageing population means more revenues).

Peer Valuation

By using implied valuation analysis, we can determine the share price.

Under P/E Multiple: Peer Median P/E is 14.08x, UNH EPS is 23.08, thus the implied share price is $324.97, a downside of 8.9%.

Under EV/EBITDA Multiple: Peer Median EV/EBITDA is 9.95x, UNH EBITDA is 34.9B, and it currently has 905.67M shares outstanding. Thus, the implied share price is $383.42, an upside of 4.8%.

Peer Analysis highlights that the current trading price is in line within its fair value. UNH is trading at 15.93x P/E, which is higher than the industry average of 13.92, indicating a slight premium. It's clear investors are cautious of flat margins and slowing Medicare Advantage growth, but may be undervaluing UNH's market leadership and scale.

A base, bear or bull scenario can all occur, but the most probable would be the base. Both the DOJ investigations and flat margins seem like short-term noise. If UNH clears investigations and fixes its operations, its clear margins can rise again. It's essential to understand the risks and catalysts that drive these factors.

Key Risks / Concerns

1. Medical Cost Inflation: You may have noticed the stat, MLR, which stands for Medical Loss Ratio. It's essentially insurance premium revenues that are spent on medical care costs/claims. The concern is that the MLR is rising faster than revenues; this ratio increased to 85.5% in 2024 from 83.2% in 2023. Increasing expenditures erode margins and profitability heavily. All companies in this industry are facing this problem, but due to UNH's messy management and fraud claims, this could reach 90% this year.

2. Legal Challenges: Ongoing scrutiny from the DOJ hasn't stopped yet. Any critical findings can put a significant blow to UNH's reputation.

3. New Regulatory Risks: The new "Patients over Profit Act" would stop insurance companies (like UNH) from buying up medical practices through subsidiaries (like Optum) if implemented. This would force the separation of UNH and Optum. It's unlikely this would happen under Trump's Administration, but regulatory risks lead to uncertainty for the future.

4. Massive Guidance Cuts: UNH is aware of the cost constraints and cut EPS guidance from $28 to $16.

5. Leadership Turmoil: Management is messy, multiple CEOs, and mass layoffs are a signal of bad operational inefficiency.

Catalysts

1. Market Leadership & Scale: UNH is the largest healthcare group by revenue and market cap. Revenues are still going strong, with an 8% increase YoY. UNH is global and has the resources to change operations around.

2. Ageing population and demand: One concern is that Medicare Advantage will plateau, but as the population ages, the demand for care will increase. It's unlikely for membership to plateau but instead increase further.

3. Investing in Research, Technology, and Innovation: UNH invests over $5 billion annually in R&D and is embedding AI applications into operations, enhancing service efficiency. This could be the key to reducing MLR.

Conclusion

This case is mixed. UNH faces a lot of short-term tailwinds (legal issues, medical inflation, operational/management inefficiencies), but in the long term, fundamentals show the upside is there. The majority of analysts are recommending a buy, suggesting the markets see this as a temporary setback rather than a structural decline. There's evidence of this, as UNH share price is slowly climbing back up.

What UNH and its peers need to address is how it's going to combat the rising Medical claim costs, as that has the most significant fundamental impact.

Considerations:

• If you believe healthcare is recession-resistant and legal costs are one-time, this could be a buying opportunity.

• If you're concerned about execution risk and regulatory threats, wait for more clarity.

• The company's size and market position provide a margin of safety, but near-term volatility is likely.

Disclaimer: The content provided on this website is for general information and educational purposes only. It is not intended to, and does not, constitute financial advice, investment advice, or a recommendation to engage in any financial activity. RNEquityInsights is not authorised or regulated by the Financial Conduct Authority (FCA) and does not provide regulated investment services or advice.